John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$244M |
| 2 |
Pfizer
PFE
|
+$234M |
| 3 |
Nike
NKE
|
+$201M |
| 4 |
Tesla
TSLA
|
+$200M |
| 5 |
S&P Global
SPGI
|
+$196M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$305M |
| 2 |
Advanced Micro Devices
AMD
|
+$241M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$231M |
| 4 |
Merck
MRK
|
+$199M |
| 5 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.1% |
| 2 | Healthcare | 11.63% |
| 3 | Consumer Discretionary | 11.09% |
| 4 | Financials | 10.76% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1601
MediaAlpha
MAX
$787M
| $1.6M | ﹤0.01% |
+78,630
| New | +$1.26M |
|
1602
Valaris
VAL
$5.95B
| $1.6M | ﹤0.01% |
21,266
-3,298
| -13% | -$221K |
|
1603
Larimar Therapeutics
LRMR
$432M
| $1.6M | ﹤0.01% |
210,472
+176,443
| +519% | +$1.37M |
|
1604
Pliant Therapeutics
PLRX
$73.7M
| $1.59M | ﹤0.01% |
+107,024
| New | +$1.77M |
|
1605
New York Times
NYT
$11.1B
| $1.59M | ﹤0.01% |
36,888
-295,650
| -89% | -$13.5M |
|
1606
Harmony Gold Mining
HMY
$14.3B
| $1.59M | ﹤0.01% |
195,100
-80,800
| -29% | -$516K |
|
|
AVNS
1607
DELISTED
Avanos Medical
AVNS
| $1.59M | ﹤0.01% |
79,982
+24,272
| +44% | +$469K |
|
1608
Blackstone Secured Lending
BXSL
$5.78B
| $1.59M | ﹤0.01% |
51,066
-65,231
| -56% | -$1.91M |
|
|
BIG
1609
DELISTED
Big Lots, Inc.
BIG
| $1.59M | ﹤0.01% |
367,160
-218,038
| -37% | -$1.15M |
|
1610
Rio Tinto
RIO
$174B
| $1.59M | ﹤0.01% |
24,900
| – | – |
|
|
TBMC
1611
DELISTED
Trailblazer Merger Corp I
TBMC
| $1.59M | ﹤0.01% |
150,000
| – | – |
|
1612
Diebold Nixdorf
DBD
$2.3B
| $1.58M | ﹤0.01% |
+45,987
| New | +$1.48M |
|
|
SRG
1613
Seritage Growth Properties
SRG
$119M
| $1.58M | ﹤0.01% |
164,108
+54,940
| +50% | +$516K |
|
|
VRE
1614
DELISTED
Veris Residential
VRE
| $1.58M | ﹤0.01% |
103,987
-30,485
| -23% | -$461K |
|
1615
Robert Half
RHI
$4.6B
| $1.58M | ﹤0.01% |
19,899
-29,918
| -60% | -$2.41M |
|
1616
iShares US Healthcare Providers ETF
IHF
$1.23B
| $1.58M | ﹤0.01% |
28,900
+10,125
| +54% | +$538K |
|
1617
Ituran Location and Control
ITRN
$1.01B
| $1.57M | ﹤0.01% |
56,305
-6,847
| -11% | -$181K |
|
1618
Granite Ridge Resources
GRNT
$666M
| $1.57M | ﹤0.01% |
242,072
-51,272
| -17% | -$301K |
|
1619
Grindr
GRND
$2.73B
| $1.57M | ﹤0.01% |
155,293
-53,868
| -26% | -$479K |
|
1620
Coty
COTY
$2.35B
| $1.57M | ﹤0.01% |
131,460
| – | – |
|
1621
Itron
ITRI
$4.32B
| $1.57M | ﹤0.01% |
16,966
-50,008
| -75% | -$4.03M |
|
1622
Aon
AON
$75.3B
| $1.57M | ﹤0.01% |
+4,700
| New | +$1.46M |
|
1623
Baker Hughes
BKR
$61.4B
| $1.57M | ﹤0.01% |
46,817
-7,883
| -14% | -$243K |
|
1624
OGE Energy
OGE
$9.49B
| $1.57M | ﹤0.01% |
45,712
| – | – |
|
1625
Adobe
ADBE
$109B
| $1.57M | ﹤0.01% |
3,106
-1,097
| -26% | -$629K |
|
Similar funds
John Overdeck's Q1 2024 Portfolio in Review
As of Q1 2024, John Overdeck held 3,518 positions worth $42.6B, down 2.1% from $43.5B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
John Overdeck withdrew a net $4.42B in Q1 2024, closing 532 positions and reducing 1,392 holdings. Its most notable exit was Rivian, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, John Overdeck opened a new position in Pfizer worth $234M.
- John Overdeck's largest Q1 2024 buy was Pfizer: 8,419,014 shares worth $234M.
- John Overdeck added most to Gilead Sciences in Q1 2024, an estimated $244M increase.
- John Overdeck's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $305M.
- John Overdeck fully exited Rivian in Q1 2024, selling an estimated $158M.
- John Overdeck's ten largest holdings make up 9% of its $42.6B portfolio in Q1 2024.
- John Overdeck opened 408 new positions and closed 532 in Q1 2024.
- John Overdeck's portfolio value fell 2.1% quarter-over-quarter to $42.6B.
Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.